Viral Pneumonia

Viral pneumonia is an acute infection of the lung parenchyma caused by respiratory viruses that directly damage the alveoli and surrounding tissues. Unlike bacterial forms, which often present with abrupt onset of fever and purulent sputum, viral pneumonia tends to manifest with persistent cough, fever, myalgia, and progressive breathlessness, sometimes followed by secondary bacterial superinfection. Influenza viruses, respiratory syncytial virus, adenovirus, and coronaviruses remain among the most frequent culprits, though emerging viral pathogens continue to challenge clinicians worldwide.

Diagnosis of viral pneumonia relies on a combination of imaging findings, such as bilateral infiltrates on chest radiographs or ground-glass opacities on CT scans, and laboratory tools, including viral PCR assays and serology. Management is largely supportive, focusing on adequate oxygenation, hydration, and fever control. Antiviral therapies, such as neuraminidase inhibitors for influenza or specific agents for other viruses, are prescribed when appropriate and most effective if initiated early. In severe cases, intensive care with mechanical ventilation or extracorporeal support may be required.

Preventive strategies are equally critical. Seasonal influenza vaccination, COVID-19 immunization, and targeted protection for vulnerable groups, such as older adults and immunocompromised individuals, substantially reduce incidence and severity. Public health measures, including hand hygiene and infection control practices, also limit transmission. With advances in molecular diagnostics and vaccine development, the outlook for viral pneumonia management continues to evolve, highlighting the importance of integrating prevention, early recognition, and tailored therapy in reducing global disease burden.